Tenax Therapeutics Insider Receives 80k Stock Options in July 2025

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. (TENX) – Form 4 filing dated 07/03/2025

The filing reports equity incentive activity for Robyn Hunter, a director of Tenax Therapeutics. On 07/01/2025 Ms. Hunter received a new stock-option grant for 80,000 shares of common stock at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. Following this grant she directly holds:

• 80,000 options (strike $5.75; granted 07/01/2025)
• 4 options (strike $992; expiry 06/09/2032)
• 100,000 options (strike $5.94; expiry 12/10/2034)

No open-market purchases or sales of Tenax common shares are reported; all transactions involve derivative securities (stock options). The filing reflects a routine equity award to a non-employee director and does not modify direct share ownership.

Insights

Corporate Governance Analyst

TL;DR: Routine director option grant; neutral governance impact.

The 80 k option award aligns with typical non-employee director compensation practices for small-cap biotech firms. Because it is a grant—not a market purchase—it does not convey incremental demand for TENX shares, nor does it alter cash position or control dynamics. The strike ($5.75) and 10-year term match prevailing incentive structures, encouraging long-term alignment without immediate dilution (exercise contingent on future price appreciation). Overall, the filing is administratively important but not materially price-sensitive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunter Robyn

(Last) (First) (Middle)

101 GLEN LENNOX DRIVE, SUITE 300

(Street)

CHAPEL HILL NC 27517

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TENAX THERAPEUTICS, INC. [ TENX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.75	07/01/2025		A		80,000		07/01/2026	07/01/2035	Common Stock	80,000	$0.00	80,000	D
Stock Option (right to buy)	$992							06/09/2023	06/09/2032	Common Stock	4		4	D
Stock Option (right to buy)	$5.94							12/10/2025	12/10/2034	Common Stock	100,000		100,000	D

Explanation of Responses:

	/s/ S. Halle Vakani, as Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What new options did Tenax Therapeutics (TENX) grant to director Robyn Hunter?

80,000 stock options with a $5.75 strike price, exercisable 07/01/2026 and expiring 07/01/2035.

Did the Form 4 report any open-market share purchases or sales by the director?

No. The filing discloses only stock-option grants; no common-stock transactions were reported.

How many Tenax Therapeutics options does Robyn Hunter now hold in total?

After the reported grant, she directly holds 180,004 options across three awards.

What is the significance of the $5.75 exercise price?

It represents the cost per share Ms. Hunter must pay to convert the options into common stock; value is realized only if TENX trades above $5.75 after vesting.

When will the newly granted options become exercisable?

The 80,000-share option vests and becomes exercisable on 07/01/2026.